- Home
- PESI vs ACRS Comparison
PESI vs ACRS Comparison
Compare PESI & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PESI
- ACRS
- Stock Information
- Founded
- PESI 1990
- ACRS 2012
- Country
- PESI United States
- ACRS United States
- Employees
- PESI N/A
- ACRS N/A
- Industry
- PESI Environmental Services
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- PESI Industrials
- ACRS Health Care
- Exchange
- PESI Nasdaq
- ACRS Nasdaq
- Market Cap
- PESI 190.6M
- ACRS 165.7M
- IPO Year
- PESI 1992
- ACRS 2015
- Fundamental
- Price
- PESI $9.99
- ACRS $1.45
- Analyst Decision
- PESI
- ACRS Strong Buy
- Analyst Count
- PESI 0
- ACRS 8
- Target Price
- PESI N/A
- ACRS $9.71
- AVG Volume (30 Days)
- PESI 115.6K
- ACRS 755.2K
- Earning Date
- PESI 08-07-2025
- ACRS 08-06-2025
- Dividend Yield
- PESI N/A
- ACRS N/A
- EPS Growth
- PESI N/A
- ACRS N/A
- EPS
- PESI N/A
- ACRS N/A
- Revenue
- PESI $59,419,000.00
- ACRS $17,777,000.00
- Revenue This Year
- PESI $23.71
- ACRS N/A
- Revenue Next Year
- PESI $86.33
- ACRS $11.77
- P/E Ratio
- PESI N/A
- ACRS N/A
- Revenue Growth
- PESI N/A
- ACRS N/A
- 52 Week Low
- PESI $6.25
- ACRS $1.05
- 52 Week High
- PESI $16.25
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- PESI 50.76
- ACRS 51.96
- Support Level
- PESI $9.96
- ACRS $1.37
- Resistance Level
- PESI $10.31
- ACRS $1.59
- Average True Range (ATR)
- PESI 0.42
- ACRS 0.10
- MACD
- PESI -0.11
- ACRS -0.01
- Stochastic Oscillator
- PESI 28.74
- ACRS 28.57
About PESI Perma-Fix Environmental Services Inc.
Perma-Fix Environmental Services Inc is a provider of both nuclear services and the management of nuclear and mixed waste. The company operates through two segments: The treatment segment offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.